0001176309 false 0001176309 2022-06-30 2022-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 30, 2022

 
ORAMED PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)

 

delaware

001-35813

98-0376008

(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)

 

1185 Avenue of the Americas, Third Floor, New York, New York

10036

(Address of Principal Executive Offices) (Zip Code)

 

844-967-2633

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol   Name of each exchange on which registered
Common Stock, par value $0.012   ORMP  

The Nasdaq Capital Market,

Tel Aviv Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

Item 5.07.  Submission of Matters to a Vote of Security Holders.

 

On June 30, 2022, Oramed Pharmaceuticals Inc. (the "Company") held its 2022 Annual Meeting of Stockholders (the "2022 Annual Meeting"). The final voting results at the 2022 Annual Meeting are set forth below.

 

Proposal No. 1 — Re-election of Directors.

 

The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows:

 

Director Name  For  Against  Abstain  Broker Non-Votes
             
Dr. Miriam Kidron   10,024,872    1,205,072    50,188    9,294,164 
                     
Nadav Kidron   10,874,166    356,111    49,855    9,294,164 
                     
Dr. Arie Mayer   9,749,693    1,468,102    62,337    9,294,164 
                     
Yadin Rozov   10,966,776    247,919    65,437    9,294,164 
                     
Leonard Sank   10,755,234    456,924    67,974    9,294,164 

 

 Proposal No. 2 — Non-Binding Advisory Vote on the Compensation of Named Executive Officers.

 

The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s Named Executive Officers. The votes were as follows:

 

For  Against  Abstain  Broker Non-Votes
 10,073,933    1,100,188    106,011    9,294,164 

  

Proposal No. 3 — Approval of an Amendment to the Company’s Amended and Restated 2019 Stock Incentive Plan.

 

The stockholders approved an amendment to the Company’s Amended and Restated 2019 Stock Incentive Plan. The votes were as follows:

 

For  Against  Abstain  Broker Non-Votes
 5,858,015    4,096,378    1,325,739    9,294,164 

 

Proposal No. 4 — Ratification of Independent Registered Public Accounting Firm for the 2022 Fiscal Year.

 

The stockholders ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the 2022 fiscal year. The votes were as follows:

 

For  Against  Abstain  Broker Non-Votes
 20,282,526    168,072    123,698    -   

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ORAMED PHARMACEUTICALS INC.
   
  By: /s/ Nadav Kidron
  Name: Nadav Kidron
  Title: President and CEO
     

June 30, 2022